|
Anthony A Holmes1, Steve Co1, Derek G Human2, Jacques G LeBlanc1, Andrew IM Campbell1
1 Division of Pediatric Cardiovascular and Thoracic Surgery, BC Children's Hospital, Vancouver, British Columbia, Canada
2 Division of Pediatric Cardiology, BC Children's Hospital, Vancouver, British Columbia, Canada
Correspondence Address:
Anthony A Holmes
Division of Pediatric Cardiovascular and Thoracic Surgery, BC Children's Hospital, Suite AB307, 4480 Oak Street, Vancouver, BC V6H 3V4
Canada
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0974-2069.93706
Objectives: To report the clinical outcomes (early death, late death, and rate of reintervention) and performance of the Contegra conduit as a right ventricle outflow tract implant and to determine the risk factors for early reintervention.
Methods: Forty-nine Contegra conduits were implanted between January 2002 and June 2009. Data collection was retrospective. The mean age and follow-up duration of Contegra recipients was 3.5 ± 4.6 years and 4.2 ± 2.0 years, respectively.
Results: There were three deaths (two early, one late), giving a survival rate of 93.9%. The rate of conduit-related reintervention was 19.6% and was most often due to distal conduit stenosis. Age at implantation of <3 months, receipt of a conduit of 12-16 mm diameter, and a diagnosis of truncus arteriosus were each significant contributors to the rate of reintervention.
Conclusion: The Contegra is a cost-effective and readily available solution. However, there is a limited range of larger calibers, which means that the homograft conduit (>22 mm) remains the first choice of implant in older children. The rates of reintervention are significantly higher with a diagnosis of truncus arteriosus, age at implantation of <3 months, and implantation of conduits sized 12-16 mm.
[FULL TEXT] [PDF]*
|
Search Pubmed for
